Invited Speakers

Keynote Speakers

chua

Associate Professor Melvin Chua Lee Kiang

Senior Consultant, Clinician-Scientist, Division of Radiation Oncology, National Cancer Centre Singapore

Principal Investigator, Tan Chin Tuan Laboratory of Optical Imaging, Photodynamic and Proton Therapy – Precision Radiation Oncology Programme, National Cancer Centre Singapore

Associate Professor, Duke-NUS Medical School 

Dr Melvin Chua is a Clinician-Scientist at the National Cancer Centre Singapore, and Principal Investigator of the Tan Chin Tuan Laboratory of Optical Imaging, Photodynamic and Proton Beam Therapy – Precision Radiation Oncology Programme, Division of Radiation Oncology. His research is supported by the NMRC Clinician-scientist award, and is focused on discovery and translational cancer genomics, and the development of biomarker-directed clinical trials in nasopharyngeal (NPC) and prostate cancers.

Dr Chua is a KOL on NPC and prostate cancer, and he has been invited to speak at more than 100 international meetings. He is also on the scientific advisory board for the NPC Guangzhou-Singapore Trial Network and a board member on the Head Neck Cancer International Group (HNCIG).

His other academic activities include his roles as the Associate Senior Editor of the International Journal of Radiation Oncology Biology Physics – Official journal of the American Society of Radiation Oncology and Editor-in-Chief, Annals of Nasopharynx Cancer. He also serves on the International Education Steering Group and the Asia-Pacific Regional Council of the American Society of Clinical Oncology (ASCO). He has published over 80 peer-reviewed papers, with a H-index of 23, including highly cited articles in the New England Journal of Medicine, Lancet, Nature, Cell, Journal of Clinical Oncology and JAMA Oncology.

park

Professor Sung Yong Park, Ph.D.

Chief Proton Physicist & Professor
National Cancer Centre Singapore

Currently, Sung Yong Park, Ph.D., is Chief Proton Physicist at National Cancer Centre Singapore and Professor at the National University of Singapore. He has over 25 years of clinical working experience from several institutions and has held Chief position in two institutions for over 18 years. During his carrier he has been involved in setting up programs at two new Radiation Oncology Departments including Proton therapy, IMRT/IGRT, HDR, Tomotherapy, and SRS/SBRT, and has been instrumental in selection, commissioning/acceptance and training of staff. In particular, he implemented the launch of National Cancer Center Proton Therapy Program in Korea and worked for the McLaren Proton Therapy Project in US. In addition, he has established the 1st medical physics resident and fellowship program at National Cancer Center in Korea.

His research experience and expertise in the field has led to his involvement with several prestigious scientific groups including membership in IEC TC 62C Working Party on Light Ion Therapy, AAPM Task Group No. 199 and Task Group No. 224, and etc.

He has published more than 118 research articles and given more than 78 invited talks. He has also received several research grants and patents. His current research interest includes Range Uncertainties in Proton Therapy, Automation of Quality Assurance, Proton Imaging, and Proton Therapy Dosimetry.

yom

Professor Sue S. Yom MD, PhD, MAS, FASTRO

Vice Chair of Strategic Advisory and Irwin Mark Jacobs and Joan Klein Jacobs Distinguished Professor in Head and Neck Cancer Radiation Oncology
Department of Radiation Oncology
University of California, San Francisco

Dr. Sue S. Yom, MD, PhD, MAS, FASTRO is the Vice Chair of Strategic Advisory and Irwin Mark Jacobs and Joan Klein Jacobs Distinguished Professor in Head and Neck Cancer Radiation Oncology. She is also Director of the Head and Neck, Cutaneous, and Thoracic Radiation Oncology Services at the University of California, San Francisco.

She completed undergraduate studies at Rice University, medical school at the University of Pennsylvania, residency at the M. D. Anderson Cancer Center, and assistant, associate and full professorship ranks at UCSF. She holds a PhD in English from the University of Pennsylvania as well as a Master’s degree in Clinical Research from UCSF.

At UCSF, she has led nationally recognized programs in head and neck, thoracic and cutaneous radiation oncology for well over a decade. She has developed and led multiple clinical trials, both within UCSF and across sites nationwide and overseas. She is interested in the late-stage evaluation of novel molecular targeted agents and immunotherapies as well as technical advances in radiation therapy and radioprotection. Her research has entailed novel regimens incorporating radiation therapy as well as collaboration with laboratory-based investigators to identify patient, tumor, and technical characteristics that influence prognosis, response, and toxicity, including tissue, blood, and imaging-based biomarkers. She has special interests in virally driven malignancies associated with humanpapillomavirus, Epstein-Barr virus and Merkel cell polyomavirus. She received NCI support for the international protocols NRG-HN002 and NRG-HN005, which explored deintensification of radiation in good-prognosis oropharyngeal cancer patients. She serves as the quality of life chair of NRG-HN001, investigating biomarker-directed treatment for nasopharyngeal cancer patients. She received an NCCN Young Investigator Award for a decision support intervention for patients with lung cancer. She conducted research on biomarkers of nicotine metabolism and participates in grants from the NIH and California Tobacco-Related Disease Research Program to enhance tobacco cessation treatment capacity at the UCSF Helen Diller Family Comprehensive Cancer Center.

Within the UCSF HDFCCC, she is a full member affiliated to the Molecular Oncology Program and Clinical Research Leadership Group and co-chairs the Oral, Head and Neck Site Committee guiding clinical trial selection and activation at UCSF. Nationally, she serves as President of the American Radium Society, Chair of the Appropriate Use Committee guidelines for radiation oncology, and Deputy Editor at the International Journal for Radiation Oncology Biology Physics. This latter role involves editorial responsibilities, staff management, and educational and promotional activities related to the ASTRO family of journals and ASTRO generally. She is a member of the NRG Oncology Head and Neck Steering, Radiation Oncology, and Publications Committees, the National Cancer Institute Head and Neck Recurrent/Metastatic Disease Task Force, and the NCCN Head and Neck Cancers guidelines committee. She is the Co-Chair (Radiation Oncology) of the Head and Neck Steering Committee of the National Cancer Institute, which guides development of NCI-funded national clinical trials in head and neck cancer. She serves on expert head and neck cancer resource panels for both ASCO and ASTRO and she served as a national written or oral boards examiner for the American Board of Radiology for several years. She has been listed in Best Doctors in America continuously since 2009.

Invited Speakers

foote

A/Prof Matthew Foote

Staff Specialist Radiation Oncologist
Princess Alexandra Hospital, Brisbane
State Lead Radiation Oncologist, ICON Cancer Care

Associate Professor Matthew Foote is a Radiation Oncologist who specialises in the management of malignant and benign brain and spine tumours. Commencing at the Princess Alexandra Hospital in 2010 and Greenslopes Private Hospital in 2012, A/Prof Foote established and is Co-Director of the Gamma Knife Centre of Queensland and is a founding member of the Stereotactic Interest Group of Australasia (SIGA). A/Prof Foote is the State Lead Radiation Oncologist for ICON Cancer Care and has been involved in the establishment of national stereotactic networks. He is a board member of the International Stereotactic Radiosurgery Society (ISRS) and was recently awarded University of Toronto Alumnus of the Year in recognition of services to the field of radiation oncology. A/Prof Foote is experienced in the development and completion of clinical trials and has authored over 100 peer-reviewed publications many in the field of brain and spine tumours.

Dr Pearly Khaw

Consultant Radiation Oncologist
Lead Radiation Oncologist, Gynae-Tumour Stream
Peter MacCallum Cancer Centre

Dr Pearly Khaw is currently the lead Radiation Oncologist in Gynae-Oncology at the Peter MacCallum Cancer Centre. She has been involved in the clinical management of women with Gynaecological cancers since 2005.

She is also a clinical researcher and is actively involved in ANZGOG, the leading Clinical Trials Group for Australia and New Zealand. She is currently a Board Director and Chair of the Quality Assurance Committee with ANZGOG, as well as a member of the Research Advisory Committee and the Uterine Tumour Type Working Group.

She led the Radiation Oncology Quality Assurance Program of the PORTEC-3 trial in Australia & NZ, through the Trans-Tasman Radiation Oncology Group (TROG), in conjunction with ANZGOG. She is currently the Radiation Oncology lead involved in the development of a number of new trials at ANZGOG, including ADELE which will be another TROG collaboration.

Dr Khaw has also led the formation of the Radiation Oncology subspecialty group within both ANZGOG and through RANZCR, in an effort to raise the profile of this craft group. She pioneered the Radiation Oncology Workshop at the ANZGOG ASM and facilitated this event with Dr Viet Do until 2019, providing others with an opportunity to learn about the art of Radiation Oncology in the management of Gynae malignancies.

A/Prof Tomas Kron

Director of Physical Sciences
Peter MacCallum Cancer Centre

Associate Professor Tomas Kron was born and educated in Germany. After his PhD he migrated to Australia in 1989 where he commenced his career in radiotherapy physics. From 2001 to 2005 he moved to Canada where he worked at the London Regional Cancer Centre on the commissioning of one of the first tomotherapy units. In 2005, Tomas became principal research physicist at Peter MacCallum Cancer Centre in Melbourne, Australia where he recently accepted an appointment as Director of Physical Sciences. He is certified to work as a radiation oncology medical physicist in Australasia, North America and Europe. Tomas holds academic honorary appointments on a professorial level at Monash, RMIT and Wollongong Universities. He has an interest in dosimetry of ionising radiation, image guided radiotherapy, clinical trials and education of medical physicists demonstrated by more than 230 papers in refereed journals.

Over the years Tomas Kron has maintained an interest in education reflected in 75 invited conference presentations, consultancies for the International Atomic Energy Agency (IAEA), and involvement in workshops and training in Australasia. In this capacity he has organised a 5 day workshop on high dose rate brachytherapy in 2006 and two workshops on IGRT in 2008 and 2010. Tomas serves on the editorial board of several international journals including Radiother. Oncol, Clinical Oncol. and TCRT, has organised conferences and was convenor of the 17th International Conference on the Use of Computers in Radiation Therapy (ICCR) in 2013 in Melbourne. In the same year he was awarded the Distinguished Services Award of the Australasian College of Physical Scientists and Engineers in Medicine (ACPSEM) and nominated as one of 50 medical physicists featured at the International Conference of Medical Physics (ICMP) in Brighton, UK, September 1 to 4, to celebrate the 50th anniversary of the International Organization for Medical Physics (IOMP). In 2014 he was awarded an Order of Australia Medal (OAM) for services to medicine, research and education.

A/Prof Chee Khoon Lee

Director, Clinical Research Unit
St George Hospital
Associate Professor of Medicine & Senior Research Fellow
NHMRC Clinical Trials Centre, University of Sydney

A/Prof Chee Khoon Lee is a medical oncologist with a subspeciality interest in thoracic malignancies. He obtained his medical degree from The University of Sydney. He completed his clinical training in internal medicine and medical oncology at St George and Prince of Wales Hospitals. He has Master degrees in clinical epidemiology and biostatistics. He obtained his PhD from the University of Sydney for methodological work in better conduct of cancer clinical trials involving biomarkers.

A/Prof Lee is the Director of the Clinical Research Unit at St George Hospital. He is also an associate professor of medicine and senior research fellow at the NHMRC Clinical Trials Centre of the University of Sydney. He is a study co-chair of five multi-center clinical trials and also a principal investigator for >70 clinical trials that investigate novel therapeutic agents for lung and gynaecological malignancies.

A/Prof Joerg Lehmann

Principal Medical Physicist, Calvary Mater Newcastle

Joerg is an accredited Radiation Oncology Medical Physics. He works at Calvary Mater Newcastle as Principal Medical Physicist responsible for implementation and development.

Joerg’s research interest include dosimetry, quality assurance, image guidance for radiotherapy treatments and data mining. He is active in radiotherapy dosimetry audits, he works as TROG QA physicist and he currently serves as chair of the Global Quality Assurance of Radiation Therapy Clinical Trials Harmonisation Group (GHG), a collaborative group of international Radiation Therapy Quality Assurance (RTQA) Groups harmonizing and improving RTQA for multi-institutional clinical trials.   Joerg is a member of the ESTRO SGRT working group and of AAPM TG 360 “Performance validation of surrogate assessment systems in the context of medical physics applications.”

Joerg holds honorary faculty appointments with the University of Newcastle and the University of Sydney.

Joerg frequently engages in photography. He has co-founded “Photography in Medical Physics” (PiMP), a photography competition celebrating the joy and excitement of Medical Physics. The idea for PiMP was born at the 2014 TROG ASM, and the competitions has been held annually since. (www.photographyinmedicalphysics.com)

Dr Jeremiah de Leon

Radiation Oncologist
Clinical/Program Lead MRI Linac
GenesisCare

Jeremy completed a Bachelor of Science in Bioinformatics prior to graduating with a Bachelor of Medicine with Honours in 2006 from the University of Sydney. He completed his radiation oncology training at Liverpool, Campbelltown and Canberra Hospitals, followed by a Fellowship at the Royal North Shore Hospital. Jeremy subsequently took up a staff specialist position at the Illawarra/ Shoalhaven Cancer Therapy Centres prior to joining GenesisCare St Vincent, Sydney as the Program/ Clinical Lead of the MRI Linac leading clinical implementation, protocol development and research. Jeremy’s clinical interests are upper GI, urogenital, lung, breast, head and neck and stereotactic radiotherapy. Jeremy and the GenesisCare St Vincent MRI Linac team are the most experienced team in Australia using the fully adaptive Adapt to Shape workflow, having treated over 40 patients and over 300 fractions using this technique since July 2020. The GenesisCare St Vincent team has treated multiple sites using the MRI Linac including stereotactic prostate and metastasis (pancreas, adrenal, nodal and bone), bladder and prostate bed.

A/Prof Mark Pinkham

Radiation Oncologist
Gamma Knife Centre of Queensland, Princess Alexandra Hospital and ICON Cancer Care, Brisbane

Mark Pinkham BM BCh MA(Hons)(Oxon) FRANZCR is a full-time Radiation Oncologist at Princess Alexandra Hospital (PAH) where he is the Director of Radiation Oncology Research. He also works with ICON Cancer Care at Greenslopes Private Hospital and North Lakes, Brisbane, Queensland. He is an Adjunct Professor at Queensland University of Technology and Honorary Associate at the NHMRC Clinical Trials Centre (University of Sydney). His clinical practice involves caring for many patients with brain tumours, including brain metastases. He is Clinical Lead for the nationally recognised eVIQ brain metastases stereotactic radiosurgery (SRS) guidelines and Chair of the SRS Working Group within TROG, a collaborative to ensure safety and consistent quality of intracranial SRS within clinical trials in Australia and New Zealand. He is a member of the trial management committee for two TROG trials in brain metastases (Local HER-O 16.02 and OUTRUN 17.02). To date he has been awarded over AU$10.7 million in related grant funding as CI. He has published 30 peer-reviewed papers, 2 book chapters and over 40 conference abstracts.

A/Prof Shankar Siva

Consultant Radiation Oncologist
Peter MacCallum Cancer Centre

Associate Professor Shankar Siva is a Radiation Oncologist and current Cancer Council Victoria (CCV) Colebatch Fellow. He leads the Stereotactic Ablative Body Radiotherapy (SABR) program at the Peter Mac and is internationally recognised for his work in high technology radiotherapy delivery. He completed his PhD with the Molecular Radiation Biology (Martin) Laboratory focusing on translational investigations in precision high-dose lung radiotherapy. He published the first original research from Australia on the use of the SABR technique.

Shankar leads multiple clinical trials in the treatment of lung and urological cancers at the Peter Mac, and is chair of five Trans Tasman Radiation Oncology Group (TROG) studies in the fields of oligometastases, lung, prostate and kidney cancers. His international commitments include positions on the Board of Directors of the Radiosurgery Society (RSS), the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) committee, American Society of Radiation Oncology (ASTRO) Science Council, and Course Director of European Society for Radiotherapy (ESTRO) SBRT Asia. At an Australasian level, he is Co-Chair of the TROG Genitourinary Group, a member of Management Advisory Committee (MAC) of the Australasian Lung Cancer Trials Group (ALTG), amongst other leadership roles. He has research interests in high-tech radiotherapy delivery, SABR and radiation immunology.

 

ASM Countdown

Important Dates

Registration

Now Open

Early Bird Registration Closes

5 February 2021